IDH2 and central nervous system cancer: Lately, the US Food and Drug Administration (FDA) greenlit vorasidenib, a brain-permeable small molecule targeting mutant IDH1/2 proteins, marking a pivotal change in the therapeutic approach for IDH-mutant gliomas (26).